Chippenham, UK, 17 May 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, will hold a Capital Markets Event in London for analysts and investors in the afternoon, Wednesday 28 June 2017.
The agenda will focus on Vectura’s unique integrated inhaled drug development platform and will include a pipeline overview. James Ward-Lilley, Chief Executive Officer, will host the event with members of the Executive Leadership and senior management teams.
Invitations and a detailed agenda will follow in due course. The venue will be Etc. Venues, Fenchurch Street, 8 Fenchurch Place, London, EC3M 4PB.
- ENDS -
|Vectura Group plc
Andrew Derodra – Chief Financial Officer
Fleur Wood – Director Communications
Elizabeth Knowles – Director Investor Relations and Analysis
|+44 (0)1249 667700|
|Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson
+44 (0)20 3709 5700
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and “smart” nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.
Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com.